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Abstract: Background. Natural immunity against cytomegalovirus
(CMV) can control virus replication after solid organ transplantation;
however, it is not known which components of the adaptive immune
system mediate this protection. We investigated whether this
protection requires human leukocyte antigen (HLA) matching
between donor and recipient by exploiting the fact that, unlike
transplantation of other solid organs, liver transplantation does not
require HLA matching, but some donor and recipient pairs may
nevertheless be matched by chance.
Methods. To further investigate this immune control, we determined
whether chance HLA matching between donor (D) and recipient (R)
in liver transplants affected a range of viral replication parameters.
Results. In total, 274 liver transplant recipients were stratified
according to matches at the HLA A, HLA B, and HLA DR loci. The
incidence of CMV viremia, kinetics of replication, and peak viral load
were similar between the HLA matched and mismatched patients in
the D+/R+ and D/R+ transplant groups. D+/R transplants with 1
or 2 mismatches at the HLA DR locus had a higher incidence of
CMV viremia >3000 genomes/mL blood compared to patients
matched at this locus (78% vs. 17%; P = 0.01). Evidence was seen
that matching at the HLA A locus had a small effect on peak viral
loads in D+/R patients, with median peak loads of 3540 and 14,706
genomes/mL in the 0 and combined (1 and 2) mismatch groups,
respectively (P = 0.03).
Conclusion. Overall, our data indicate that, in the setting of liver
transplantation, prevention of CMV infection and control of CMV
replication by adaptive immunity is minimally influenced by HLA
matching of the donor and recipient. Our data raise questions about
immune control of CMV in the liver and also about the cells in which
the virus is amplified to give rise to CMV viremia.
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Cytomegalovirus (CMV) remains an important oppor-
tunistic pathogen in transplant patients. After liver
transplantation, the virus is associated with a range of
direct and indirect effects including hepatitis and acute
rejection (1, 2). Currently, CMV disease can be
prevented during the immediate post-transplant period
by giving antiviral drugs, either prophylactically from
the time of transplant, or preemptively upon detection
of CMV viremia (3).
Post transplant, CMV-seropositive recipients (R+)
can reactivate latent CMV as a consequence of immu-
nosuppression. In addition, the virus can be transmitted
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with a donor liver to cause primary infection in a CMV-
seronegative individual (R) or reinfection in a CMV-
seropositive individual (4). The donor/recipient (D/R)
CMV serostatus combinations are associated with
different risks of CMV viremia post transplant, D+/
R giving the highest risk, followed by D+/R+, then
D/R+ and D/R. Although it is well established
that CMV disease is less frequent in those with prior
natural immunity, it is not clear whether this protective
immunity is conferred by cytotoxic T lymphocytes or
other components of the adaptive or innate immune
systems. However, CMV disease predominantly occurs
in patients with suppressed T-cell immunity and recent
data have shown that the quality of the CD4 and CD8
response is correlated with the control of high-level
replication and consequent prevention of CMV disease
after liver, kidney, and heart-lung transplantation (5–8).
Studies of the role of CD8 T cells in controlling CMV
after liver transplantation are confounded by the fact that
transplant donors and recipients are matched on blood-
group but not on human leukocyte antigen (HLA) type,
although HLA matching can occur by chance. CD8+ T
cell-mediated control of CMV infection in a transplanted
liver is likely to be impaired when donor cells present
CMV-derived peptides on class I HLA molecules, which
are not matched to the recipient HLA type.
On this basis, we hypothesized that donors and
recipients who were, by chance, matched at HLA loci
would be better able to control CMV replication than
those patients whose transplants were not HLA
matched. In this study, we tested this hypothesis in a
cohort of patients managed by preemptive therapy and
found that control of CMV replication post transplant is
minimally influenced by HLA matching between donor
and recipient.
Materials and methods
Patients
All liver transplants (n = 331) performed from January
2003 to October 2008 at the Royal Free Hospital,
London, UK were identified from the transplant data-
base. Patients were excluded from the study if:
1. The CMV serostatus of donor or recipient before
transplantation could not be confirmed (n = 5);
2. No CMV viral load data were available post trans-
plant (n = 18);
3. They had received an experimental CMV vaccine
during the study period (n = 16) as part of a clinical
trial (9).
Patients with multiple transplants were included once
only in their highest risk D/R CMV serostatus group
(D+/R > D+/R+ > D/R+ > D/R; n = 18). This
left a total of 274 patients in this historical cohort. All
patients accepted into the liver transplant program gave
written informed consent for their laboratory results to
be analyzed for research purposes.
Detection and management of CMV viremia
Whole blood samples for CMV polymerase chain
reaction (PCR) were requested twice weekly from
inpatients and at each subsequent outpatient visit
(typically scheduled weekly for 4 weeks, then every
2 weeks thereafter).
Total nucleic acids were extracted from whole blood
using the QIAamp DNA Blood Mini Kit (QIAGEN Ltd,
Manchester, UK) until October 2006, and the Bio-
merieux EasyMag system thereafter (Biomerieux,
Marcy L’Etoile, France). Real-time PCR for quantifica-
tion of CMV DNA was performed on the TaqMan
7700/7500 system (Applied Biosystems/Lifetechnolo-
gies, Grand Island, New York, USA) using an in-house
assay targeting a 150-base pair amplicon from the CMV
UL55 gene that encodes glycoprotein B (10). Serial
dilutions of cloned amplicon (from 200 plasmid copies/
mL to 2 9 106 plasmid copies/mL) were run in
triplicate on each plate as a standard for quantification.
CMV load was calculated using Applied Biosystems
sequence detection software. The detection limit was
200 genomes/mL (equivalent to 168 international units
[IU]/mL) (11).
The standard clinical practice at the Royal Free
Hospital for preemptive therapy was followed for CMV
management throughout the study period and no
patient received antiviral prophylaxis. In accordance
with our routine protocol, if viral load exceeded 3000
genomes/mL in whole blood (equivalent to 2520 IU/
mL), the patient was treated with twice-daily intrave-
nous ganciclovir 5 mg/kg (or twice-daily oral valganci-
clovir 900 mg), with dose adjustment for renal function,
until CMV DNA was undetectable (<200 genomes/mL)
in 2 consecutive blood samples. We and others have
previously shown that the kinetics of response of CMV
load to ganciclovir and valganciclovir therapy are
equivalent (12, 13).
Virological outcome measures
Viral load measurements were obtained from the
hospital pathology database for a 90-day period com-
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mencing on the day of transplantation. The following
virological parameters were assessed:
1. Cumulative incidence of viremia >3000 genomes/mL
in the 90 days post transplant.
2. Time to viremia post transplantation. Follow up
began at the day of transplantation and person-time
at risk was calculated for each patient as the number
of days from transplantation until: (i) the last
negative CMV PCR of the follow up; or (ii) the first
CMV PCR >3000 genomes/mL; or (iii) death.
3. Trajectory of viremia (mean increase per day as a
log10 function of viral load) in patients who experi-
enced CMV viremia >3000 genomes/mL. First, a
graph was plotted of log10 CMV load against time.
The viral load time points defined in order to
calculate the trajectory were: (i) last negative sample
(<200 genomes/mL) prior to the start of the viremia;
(ii) first positive (>200 genomes/mL); (iii) peak viral
load. Viral loads in between first positive and peak
viral load were also used to calculate the trajectory. A
linear regression line was then fitted to these data,
and the trajectory during the viremic episode was
calculated using the regression coefficients. Only the
first viremic episode for each patient was considered.
Individuals without a negative sample at least 7 days
before the first positive sample were excluded, as it
would not be possible to accurately predict the start
of viremia in these cases. Trajectory was reported as
the mean increase in the viral load (log10 genomes/
mL/day).
4. Peak viral load in all patients with detectable viremia
(i.e., viral load >200 genomes/mL).
HLA matching
For each outcome of interest, the effect of HLA
matching at A, B, and DR alleles was examined. HLA
typing was performed at the Anthony Nolan Centre
using the microcytotoxicity technique as described
previously (13). Mismatches were classified as either 0
mismatches, or 1 and 2 mismatches (combined into one
group) for each of the HLA alleles.
CMV serology
The results for each outcome were additionally strat-
ified by the CMV immunoglobulin-G (IgG) status of
donors and recipients by the following D/R serostatus
groups: D/R, D/R+, D+/R+, D+/R. Recipient
CMV IgG status before transplantation was determined
using a Biomerieux VIDAS from the start of the cohort
until July 2008, after which it was carried out on an
Abbott Architect i2000 SR (Abbott Diagnostics, Abbott
Park, Illinois, USA). For recipients with multiple sam-
ples before transplantation, IgG status was based on the
sample taken closest to the date of transplantation.
CMV serological testing of donors was performed by
the host hospital and confirmed in house when samples
were available.
Data sources
Clinical and HLA data were extracted from a Microsoft
Access database maintained by the liver transplant unit
and CMV PCR data from the hospital pathology
database. These 2 sets of data were then matched
using the unique hospital number in Microsoft Access.
Statistical analysis
Sample size of the cohort was determined by the
transplantation numbers. Statistical analysis was per-
formed using Stata version 11 (StataCorp LP, College
Station, Texas, USA). Categorical variables were ana-
lyzed using chi-square or Fisher’s exact test. Kruskal–
Wallis tests were used to analyze numerical variables.
Kaplan–Meier survival analysis was used for time-
dependent analysis, with groups compared using the
log-rank test. Assessment was made for missing data
using simple descriptive statistics.
Results
Study participants
Of the 274 subjects included in the study, 102 were
female and 172 male (Table 1). CMV IgG positivity was
higher among transplant recipients (74%, 203/274) than
donors (49%, 134/274). D/R HLA mismatches at 1 or 2
loci were most frequent for HLA B (90%, 246/274),
followed by HLA A (85%, 233/274) and finally HLA DR
(84%, 231/274). The total person-time at risk was
55.8 years, and the mean length of follow up was
74.4 days. The median number of samples per patient
in the 90-days follow up post transplantation was 15
(interquartile range [IQR] 9, 24). No data were missing
with respect to clinical or demographic details of the
patients in the final dataset used for this analysis.
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A. Occurrence of high-level CMV replication (>3000
genomes/mL)
Fifty-four patients (20%) had a viral load >3000 ge-
nomes/mL within 90 days of transplantation and there-
fore received antiviral therapy. A high level of CMV
viremia during the first 90 days post transplant was
most common in the D+/R group (67%, 22/33),
followed by the D+/R+ group (23%, 23/101), and finally
the D/R+ group (9%, 9/102 (P < 0.001, chi-square
test for trend). No episodes of CMV viremia were
detected in the 90-day period following transplantation
for the D/R group.
D+/R transplants with 1 or 2 mismatches at the
HLA DR locus had a higher incidence of viremia >3000
genomes/mL (78%; 21/27), compared to patients
matched at this locus (17% [1/6]; P = 0.01 Fisher’s
exact test; Fig. 1, Table S1). No such difference was
seen in the D+/R+ or D/R+ groups. HLA matching at
HLA A or B loci had no significant effect on the
incidence of CMV viremia >3000 genomes/mL in any
of the D/R groups.
B. Time to CMV viremia >3000 genomes/mL
Survival analysis was performed on the time to viremia
post transplantation (Fig. 2). In D/R+ transplants, at
risk of CMV reactivation, the proportion with viremia at
90 days was 0.12, (95% confidence interval [CI]: 0.07,
0.64) and 0.08 (95% CI: 0.04, 0.16), respectively in the 0
and combined HLA DR mismatched groups (P = 0.12,
log-rank test, Fig. 2A). The pattern was similar with
HLA A or B mismatches (P = 0.92, and 0.73, respec-
tively, log-rank test). In the D+/R+ transplants, at risk
of reinfection or reactivation (Fig. 2B), and the D+/R
transplants, at risk of primary infection (Fig. 2C),
matching at HLA A, B, or DR loci also had no effect
on time to viremia (P = 0.14, and 0.38 and 0.06,
respectively, for D+/R+; P = 0.70, 0.23 and 0.67,
respectively, for D+/R, log-rank test).
C. Trajectory of viral load
The trajectory of viral load was analyzed among the
subgroup of individuals who experienced CMV viremia
>3000 genomes/mL. The median trajectories for the
D+/R, D+/R+, and D/R+ stratified groups were
0.17, 0.18, and 0.22 log10 genomes/mL per day,
respectively (P = 0.36, Kruskal–Wallis test).
No evidence was seen for a difference in the
trajectory of viral load with increases in the number
of mismatches at the HLA A or DR loci (Table 2). A
trend was noted suggesting that trajectories varied by
HLA B mismatches in the D+/R group, with median
trajectories of 0.37 (IQR 0.34–0.40), 0.09 (IQR 0.05–
0.20) in the 0 and combined 1 and 2 mismatch groups
(P = 0.04, Kruskal–Wallis test; Table 2).
D. Peak viral load
As expected, peak viral load varied significantly accord-
ing to D/R CMV status (P < 0.001, Kruskal–Wallis
test). Median peak viral load was 12,332 genomes/mL
in the D+/R group, 2616 genomes/mL in the D+/R+
group, and 1047 genomes/mL in the D/R+ group.
Baseline characteristics of the study population
Number %
Total no. patients 274 100
Gender
Male 172 63
Female 102 37
Median age at transplant (IQR) 51 (42–58)
Recipient CMV positive 203 74
Donor CMV positive 134 49
D R 38 14
D+ R 33 12
D R+ 102 37
D+ R+ 101 37
Viremias within 60 days of follow up
>3000 copies 54 20
>200 copies 110 40
HLA A mismatches
0 41 15
1 & 2 233 85
HLA B mismatches
0 28 10
1 & 2 246 90
HLA DR mismatches
0 43 16
1 & 2 231 84
IQR, interquartile range; CMV, cytomegalovirus; D, donor; R,
recipient; HLA, human leukocyte antigen.
Table 1
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Evidence indicates that matching at the HLA A locus
had a small effect on peak viral loads in D+/R patients
(median peak loads: 3540 genomes/mL [IQR 1575–
7496] and 14,706 genomes/mL [IQR 8131–68,854] in
the 0 and combined [1 and 2] mismatch groups,
respectively, P = 0.03). A trend was also seen for a
similar effect when these D+/R transplant recipients
were stratified according to HLA DR and HLA B
mismatches (Fig. 3; Table S2). No effect was seen for
mismatches at any HLA loci for the D/R+ and D+/R+
groups.
Discussion
The results presented herein confirm that pre-existing
natural immunity can control CMV replication after
transplantation (14), as illustrated by significantly fewer
seropositive than seronegative recipients having vire-
A
B
C
Fig 1. Impact of (A) human leukocyte antigen (HLA) A; (B) HLA B;
and (C) HLA DR mismatch on incidence of high-level cytomegalo-
virus (CMV) viremia (>3000 genomes/mL) according to donor (D)/
recipient (R) CMV serostatus. Proportion of patients in each group
with high-level viremia is shown. Blue bars: no mismatch; green bars:
1 or 2 mismatches. Error bars show 95% confidence intervals.
A D-R+
B D+R+
C D+R-
Fig. 2. Kaplan–Meier analysis of the impact of human leukocyte
antigen (HLA) A, B, and DR mismatch on the time elapsed between
transplantation and onset of high-level viremia (>3000 genomes/mL)
according to donor (D)/recipient (R) cytomegalovirus serostatus: (A)
DR+; (B) D+R+; (C) D+ R.
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mia when challenged with seropositive donor organs,
and by a significantly lower peak viral load. This control
may reflect a range of immune effectors including
antibodies, T cells, and NK cells. The present study
indicates that HLA matching in liver transplantation
explained only a small proportion of the protective
effect conferred by pre-transplant immunity against
CMV. The weak associations we observed were in the
primary infection D+/R group, where we saw an
increased incidence of CMV viremia >3000 genomes/
mL in the presence of mismatches at the HLA DR
locus, and an elevated peak viral load in D+/R
patients when mismatches at the HLA A and HLA DR
loci were present. A trend suggests that trajectories
varied by HLA B mismatches in the D+/R group. Our
study combines data from a large transplant database at
a single UK transplant center and, based upon the
completeness of the dataset, minimal loss to follow up,
and minimal chance of selection bias, the results
support the general conclusion that HLA mismatch at
the 3 loci examined does not have a major impact on
the incidence or kinetics of CMV viremia after liver
transplantation in patients with pre-existing immunity
to CMV.
Microcytotoxicity was used to determine the HLA
matching for this study. Although more advanced
techniques may exist that would allow a greater level
of differentiation for mismatches, this methodology is
used in many clinical settings. We have therefore taken
a pragmatic approach to use these data. It is important
to note that we have not attempted to quantify the
immunosuppressive regimens used in all the transplant
patients included in the study; however, the transplant
center from which the data are taken uses an estab-
lished standard protocol in the majority of its patients.
It is notable that all of the effects we observed were in
the D+/R patient group. The elevated incidence of
viremia in HLA DR mismatched patients in this group is
consistent with an important role for CD4 T cells in
control of primary CMV infection in this setting (7, 8,
15, 16). Direct CD4-mediated cytotoxicity is one possi-
ble mechanism for control, and we have shown
previously that a decreased level of poly-functional
CD4 T cells correlates with viremia after liver trans-
plantation (7). Other studies have shown that, in this
context, CD4 and CD8 T cells have high levels of PD-1
and are poorly proliferative (17–19). The role of CD4 T
cells in generation of an antibody response to the
primary infection is also of potential importance.
Indeed, we recently showed that a vaccine-induced
antibody response correlated with control of CMV
viremia, and may have reduced transmission rates in
D+/R patients (9).
It is well established that, overall, D+/R patients
experience higher peak viral loads than D+/R+ or D/
R+ patients, indeed this is a key demonstration of the
effectiveness of the CMV-specific immune response
(14, 20, 21). Our analysis extends this demonstration by
suggesting that the overall elevation in peak viral load
in D+/R patients is, in part, driven by the HLA-
mismatched individuals. Nevertheless, in most cases,
the scale of the effects that we observed was small.
Hepatocytes express relatively low levels of HLA class I
and class II molecules (22, 23), providing a plausible
rationale for the minimal effect of HLA A and B
mismatching. However, we cannot estimate the impact
of expression of class I and II antigens on other cell
Trajectory (log10 genomes/mL/day) of viremia in individuals with
viremias >3000 genomes/mL according to donor (D)/recipient (R)
cytomegalovirus status and human leukocyte antigen (HLA) mismatch
level
HLA
mismatches
Total in
group
Trajectory median log
copies/mL/day (IQR) P-value*
HLA A
D R+ 0 0 –
1 & 2 6 0.18 (0.15–0.32)
D+ R+ 0 1 0.34 (0.34–0.34) 0.16
1 & 2 15 0.11 (0.07–0.18)
D+ R 0 1 0.34 (0.34–0.34) 0.22
1 & 2 9 0.12 (0.06–0.23)
HLA B
D R+ 0 0 –
1 & 2 6 0.18 (0.15–0.32)
D+ R+ 0 0 –
1 & 2 16 0.12 (0.09–0.24)
D+ R 0 2 0.37 (0.34–0.40) 0.04
1 & 2 8 0.09 (0.05–0.20)
HLA DR
D R+ 0 1 0.15 (0.15–0.15) 0.38
1 & 2 5 0.2 (0.17–0.32)
D+ R+ 0 2 0.23 (0.15–0.31) 0.27
1 & 2 14 0.11 (0.07–0.18)
D+ R 0 1 0.34 (0.34–0.34) 0.22
1 & 2 9 0.12 (0.06–0.23)
Numbers in this table do match those in Table 1, as it was not
possible to calculate trajectory in each case owing to missing data.
*Kruskall–Wallis test.
IQR, interquartile range.
Table 2
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types, such as Kupfer cells (for class II) and bile duct or
vascular epithelia (for class I).
Given the data available for this study, it has not been
possible to examine the impact of HLA micropolymor-
phisms or supertypes. We therefore recommend that
other liver transplant centers analyze their data using
similar methods, and consider pooling the results to
increase sample size, which would allow finer mapping
of HLA diversity than was available in our study.
Our data raise interesting questions about the path-
ogenesis of CMV in the liver transplant setting. Our
measure of CMV replication is based on the detection
of viral DNA in whole blood. However, we do not know
the cellular origin of the virus that gives rise to this
viremia. So, while the original source of CMV in the
D+/R patients is definitely the donor liver and the
donor may reinfect a seropositive recipient in the D+R+
combination (4), liver cells may not be the major source
of virus detected in blood.
It is conceivable that a small inoculum of liver-derived
virus infects recipient cells in other organ systems
leading to amplification and consequent seeding of
viremia. Such producer cells would be susceptible to T
cell-mediated immune control because viral antigens
would be presented by recipient cells in the correct
HLA context. This possibility is supported by work with
murine CMV (MCMV) demonstrating that high-level
MCMV replication in hepatocytes had a negligible
impact on the viral load in blood, which was derived
primarily from infected endothelial cells (24). If such a
phenomenon were operating in the human system, the
effects of HLA matching would be minimized. Such a
scenario could resolve the apparent contradiction
between our current observations and the correlation
that we (and others) have documented previously in
CMV-positive liver transplant patients between a poly-
functional T-cell response and control of viremia (7, 18,
19). It could also provide a potential explanation for the
lack of association between cumulative viral load in
whole blood and CMV hepatitis in our previous studies
(25). Thus, it is possible that CMV replication in the
liver produces abnormal aminotransferase levels as a
consequence of viral lysis of the liver cells in HLA-
mismatched individuals, whereas in the HLA-matched
setting, a discrete CMV hepatitis may be driven
predominantly by the immune destruction of liver cells
as observed in hepatitis B infection. By analogy with
the MCMV model, the progeny virus resulting from
replication in donor cells would not be detected in
whole blood, as the majority remains confined within
the liver.
In conclusion, the results in this report are consistent
with the view that, in a D+ setting, while the donor
organ is the initial source of virus, cytotoxic T lympho-
cyte-mediated control of CMV replication in the liver
has minimal impact on the overall immune control of
CMV infection. These data have relevance to the use of
adoptive transfer of immune committed T cells and/or
immunization of recipients awaiting transplantation as
potential ways of reducing donor-to-recipient transmis-
sion of CMV and CMV replication post transplantation.
A
B
C
Fig. 3. Impact of (A) human leukocyte antigen (HLA) A; (B) HLA B;
and (C) HLA DR mismatch on peak viral load among all viremic (>200
genomes/mL) patients. Median peak viral load is plotted. Blue bars:
no mismatch; green bars: 1 or 2 mismatches. Error bars show
interquartile range. CMV, cytomegalovirus; D, donor; R, recipient.
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